Skip to main content

Treace John T.'s Form 4/A amendment

Amended

Treace Medical Concepts, Inc. (TMCI) · filed Jun 12, 2026

Accession no.
0001193125-26-268606
Filed
Jun 12, 2026
Trade date
Jun 10-11, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked
Original filed
Jun 11, 2026

This filing lists 2 non-derivative transactions. Open-market purchases total $99.1K. It was filed 2 days after the trade.

This amendment replaces 0001193125-26-267800 (filed Jun 11, 2026).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Treace John T.CIK 0001856380Director, Officer (Chief Executive Officer), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 10, 2026Common StockPPurchaseAcquired+14,715$4.02F2+$59,154.37,338,548Direct
Jun 11, 2026Common StockPPurchaseAcquired+9,891$4.04F5+$39,959.647,348,439Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The original Form 4, filed on June 11, 2026, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a purchase that occurred on June 10, 2026 as a total of 29,430 shares purchased when in fact 14,715 shares of the Issuer's common stock were purchased.

F2

The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9300 to $4.1000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

Includes 542,784 restricted stock units.

F4

The original Form 4, filed on June 11, 2026, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a purchase that occurred on June 11, 2026 as a total of 22,887 shares purchased when in fact 9,891 shares of the Issuer's common stock were purchased.

F5

The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9600 to $4.1700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.

F7

The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.

Read the full filing on SEC EDGAR (opens in a new tab)